Ursprung des Netzwerks ersten Grades von Wulff-Erik von Borcke
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 23 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Wulff-Erik von Borcke
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| SUMMIT THERAPEUTICS INC. | Biotechnology | Chief Executive Officer Director/Board Member Director of Finance/CFO Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Summit Therapeutics Ltd.
 Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member | |
| PULSE BIOSCIENCES, INC. | Medical Specialties | Chairman Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
Pharmacyclics, Inc.
 Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Chief Operating Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| KITE PHARMA INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Sales & Marketing | |
| BIOMEA FUSION, INC. | Pharmaceuticals: Major | Founder Director/Board Member Chief Tech/Sci/R&D Officer | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal Compliance Officer | |
Robert W. Duggan & Associates
 Robert W. Duggan & Associates Investment ManagersFinance Robert W. Duggan & Associates provides investment advisory services. The firm also offers portfolio management, financial planning, and consulting services. The company was founded by Robert W. Duggan and is headquartered in Santa Barbara, CA. | Investment Managers | Founder Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Human Longevity, Inc.
 Human Longevity, Inc. BiotechnologyHealth Technology Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| SOLIGENIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
| Georgia State University | College/University | Masters Business Admin | |
Healogix LLC
 Healogix LLC Miscellaneous Commercial ServicesCommercial Services Healogix LLC is a healthcare marketing research and consulting firm. The private company is based in Horsham, PA. The company was founded by Harris Kaplan. Harris Kaplan has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
| Kansas State University | College/University | Undergraduate Degree | |
| Moores Cancer Center | Corporate Officer/Principal | ||
TriSalus Operating Life Sciences, Inc.
 TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Director/Board Member | |
| University of California San Diego | College/University | Graduate Degree | |
| Pennsylvania State University College of Medicine | College/University | Doctorate Degree | |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| INTUITIVE SURGICAL, INC. | Medical Specialties | Director/Board Member | |
| University of Delaware | College/University | Masters Business Admin | |
| Hamilton College (New York) | College/University | Undergraduate Degree | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal | |
| KURA ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| 4D MOLECULAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
| PRINCIPIA BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
| GAMIDA CELL LTD. | Pharmaceuticals: Major | Chairman | |
Geneos Therapeutics, Inc.
 Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Biotechnology | Director/Board Member | |
| MESOBLAST LIMITED | Biotechnology | Director/Board Member | |
| CABALETTA BIO, INC. | Biotechnology | Director/Board Member | |
| State University of New York at Binghamton | College/University | Undergraduate Degree | |
| Lymphoma Research Foundation | Director/Board Member | ||
| Berlex Laboratories, Inc. | Corporate Officer/Principal | ||
| Cedar Crest College | College/University | Undergraduate Degree | |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Doctorate Degree | |
| ACLARIS THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel | |
| SEAGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of California, Santa Cruz | College/University | Undergraduate Degree | |
| CORVUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | General Counsel | |
| DERMIRA, INC. | Pharmaceuticals: Major | General Counsel | |
| Seton Hall University School of Law | College/University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 48 |
| Vereinigtes Königreich | 2 |
| Schweden | 2 |
| Australien | 2 |
Sektoral
| Health Technology | 35 |
| Consumer Services | 12 |
| Finance | 2 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 56 |
| Corporate Officer/Principal | 43 |
| Independent Dir/Board Member | 26 |
| Chief Tech/Sci/R&D Officer | 15 |
| Undergraduate Degree | 15 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Shawn Tomasello | 22 |
| Robert Duggan | 18 |
| Diane Parks | 14 |
| Mahkam Zanganeh | 14 |
| Manmeet Singh Soni | 13 |
| Ramses Erdtmann | 13 |
| Elizabeth Faust | 12 |
| Dawn Bir | 8 |
| Kenneth Clark | 7 |
| Dakota Gallivan | 7 |
| Raymond Jeffrey Kmetz | 6 |
| Kristi Miller | 5 |
| Matthew Outten | 5 |
| John Northcott | 5 |
| Danelle James | 5 |
- Börse
- Insiders
- Wulff-Erik von Borcke
- Unternehmensverbindungen
